[{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Voriconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Zambon Switzerland \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zambon Switzerland \/ Undisclosed"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Safinamide Methanesulfonate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Switzerland \/ Newron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Zambon Switzerland \/ Newron Pharmaceuticals"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Zambon Switzerland","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Riluzole","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Film, Dispersible","sponsorNew":"Zambon Switzerland \/ Zambon Switzerland","highestDevelopmentStatusID":"6","companyTruncated":"Zambon Switzerland \/ Zambon Switzerland"}]

Find Clinical Drug Pipeline Developments & Deals by Zambon Switzerland

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.

                          Product Name : Xadago

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          May 12, 2021

                          Lead Product(s) : Safinamide Methanesulfonate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Newron Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Riluzole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 29, 2021

                          Lead Product(s) : Riluzole

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Cross Research S.A.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Voriconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Aspergillosis, Allergic Bronchopulmonary.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 18, 2020

                          Lead Product(s) : Voriconazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank